Bath Psoralen Plus UVA Therapy Suppresses Keratinocyte-Derived Chemokines in Pathogenetically Relevant Cells

Overview

Journal JID Innov

Specialty Dermatology

Date 2021 Dec 15

PMID 34909726

Citations 3

Authors

Yoshifumi Kanayama

Kan Torii

Kyoko Ikumi

Akimichi Morita

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a chronic inflammatory proliferative skin disease involving various types of chemokines regulating immune cell migration, localization, and activation. Bath psoralen plus UVA (PUVA) treatment is an established phototherapy for psoriasis, but its effects on chemokine levels remain unknown. We investigated the levels of 22 serum chemokines in 20 patients with psoriasis first treated with bath PUVA therapy between 2007 and 2011 in a single center and analyzed the associations between the chemokines and disease severity (PASI) before and after therapy to investigate the mechanisms of action of bath PUVA therapy. Before bath PUVA therapy, the PASI scores correlated with the serum levels of CCL17 (r = 0.581), CCL18 (r = 0.462), CCL19 (r = 0.477), and CXCL16 (r = 0.524). After bath PUVA, the serum levels of CCL17, CCL22, CXCL1, and CXCL9 were significantly decreased. Heatmap clustering and network analysis based on statistically significant Spearman correlations among the chemokines showed distinctive changes in the chemokine signature. Our findings revealed that the levels of several chemokines correlated with the disease state of psoriasis. Furthermore, bath PUVA therapy reduced the secretion of keratinocyte-derived chemokines that induce the migration of immune cells important for psoriasis pathogenesis, partly revealing the mechanism of the therapeutic activity.

Citing Articles

Chinese Medicine as Supporting Therapy for Psoriasis: Past, Present, and Future.

Yang X, Cai W, Guo C, Chen Q Chin J Integr Med. 2022; 29(3):280-288.

PMID: 36301454 DOI: 10.1007/s11655-022-3683-8.

Determining the immune environment of cutaneous T-cell lymphoma lesions through the assessment of lesional blood drops.

Torii K, Okada Y, Morita A Sci Rep. 2021; 11(1):19629.

PMID: 34608214 PMC: 8490448. DOI: 10.1038/s41598-021-98804-0.

The Role of Chemokines in Psoriasis-An Overview.

Zdanowska N, Kasprowicz-Furmanczyk M, Placek W, Owczarczyk-Saczonek A Medicina (Kaunas). 2021; 57(8).

PMID: 34440960 PMC: 8400543. DOI: 10.3390/medicina57080754.

References

Fraticelli P, Sironi M, Bianchi G, DAmbrosio D, Albanesi C, Stoppacciaro A . Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest. 2001; 107(9):1173-81. PMC: 209276. DOI: 10.1172/JCI11517. View

Gunther C, Carballido-Perrig N, Kaesler S, Carballido J, Biedermann T . CXCL16 and CXCR6 are upregulated in psoriasis and mediate cutaneous recruitment of human CD8+ T cells. J Invest Dermatol. 2011; 132(3 Pt 1):626-34. DOI: 10.1038/jid.2011.371. View

Lowes M, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba L, Haider A . Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008; 128(5):1207-11. DOI: 10.1038/sj.jid.5701213. View

Boehncke W, Schon M . Psoriasis. Lancet. 2015; 386(9997):983-94. DOI: 10.1016/S0140-6736(14)61909-7. View

Li C, Xu M, Coyne J, Wang W, Davila M, Wang Y . Psoriasis-associated impairment of CCL27/CCR10-derived regulation leads to IL-17A/IL-22-producing skin T-cell overactivation. J Allergy Clin Immunol. 2020; 147(2):759-763.e9. PMC: 7726097. DOI: 10.1016/j.jaci.2020.05.044. View

Kagami S, Rizzo H, Lee J, Koguchi Y, Blauvelt A . Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2009; 130(5):1373-83. PMC: 2892169. DOI: 10.1038/jid.2009.399. View

Chen J, Du J, Han Y, Wei Z . Correlation analysis between IL-35, IL-36, CCL27 and psoriasis vulgaris. J Dermatolog Treat. 2019; 32(6):621-624. DOI: 10.1080/09546634.2019.1689226. View

Kubo R, Muramatsu S, Sagawa Y, Saito C, Kasuya S, Nishioka A . Bath-PUVA therapy improves impaired resting regulatory T cells and increases activated regulatory T cells in psoriasis. J Dermatol Sci. 2017; 86(1):46-53. DOI: 10.1016/j.jdermsci.2017.01.001. View

Mabuchi T, Chang T, Quinter S, Hwang S . Chemokine receptors in the pathogenesis and therapy of psoriasis. J Dermatol Sci. 2011; 65(1):4-11. DOI: 10.1016/j.jdermsci.2011.11.007. View

10.

Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A . Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010; 163(6):1282-90. DOI: 10.1111/j.1365-2133.2010.09992.x. View

11.

Nograles K, Zaba L, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T . IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009; 123(6):1244-52.e2. PMC: 2874584. DOI: 10.1016/j.jaci.2009.03.041. View

12.

Bose F, Petti L, Diani M, Moscheni C, Molteni S, Altomare A . Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis. Am J Pathol. 2013; 183(2):413-21. DOI: 10.1016/j.ajpath.2013.04.021. View

13.

Furue K, Ito T, Tsuji G, Nakahara T, Furue M . The CCL20 and CCR6 axis in psoriasis. Scand J Immunol. 2019; 91(3):e12846. DOI: 10.1111/sji.12846. View

14.

Homey B, Dieu-Nosjean M, Wiesenborn A, Massacrier C, Pin J, OLDHAM E . Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol. 2000; 164(12):6621-32. DOI: 10.4049/jimmunol.164.12.6621. View

15.

Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Asano N, Mitsui H . Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol. 2003; 111(3):592-7. DOI: 10.1067/mai.2003.114. View

16.

Kim H, Cho S, Chung B, Ahn H, Park C, Lee C . Expression of CCL1 and CCL18 in atopic dermatitis and psoriasis. Clin Exp Dermatol. 2012; 37(5):521-6. DOI: 10.1111/j.1365-2230.2011.04295.x. View

17.

Meinhardt M, Krebs R, Anders A, Heinrich U, Tronnier H . Wavelength-dependent penetration depths of ultraviolet radiation in human skin. J Biomed Opt. 2008; 13(4):044030. DOI: 10.1117/1.2957970. View

18.

Dai Y, Li Y, Zeng H, Liang X, Xie Z, Zheng Z . Effect of pharmacological intervention on MIP-1α, MIP-1β and MCP-1 expression in patients with psoriasis vulgaris. Asian Pac J Trop Med. 2014; 7(7):582-4. DOI: 10.1016/S1995-7645(14)60098-5. View

19.

Riis J, Johansen C, Vestergaard C, Bech R, Kragballe K, Iversen L . Kinetics and differential expression of the skin-related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis. Exp Dermatol. 2011; 20(10):789-94. DOI: 10.1111/j.1600-0625.2011.01323.x. View

20.

Quan C, Cho M, Shao Y, Mianecki L, Liao E, Perry D . Dermal fibroblast expression of stromal cell-derived factor-1 (SDF-1) promotes epidermal keratinocyte proliferation in normal and diseased skin. Protein Cell. 2015; 6(12):890-903. PMC: 4656211. DOI: 10.1007/s13238-015-0198-5. View